34894
document
Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome . OBJECTIVE In this study , we tested in patients with metabolic syndrome whether allopurinol through decreasing oxidative stress improves endothelial function , and ameliorates inflammatory state represented by markers of myeloperoxidase , C-reactive protein ( CRP ) and fibrinogen . METHODS In a randomized , double-blind fashion ; subjects with metabolic syndrome were treated with allopurinol ( n = 28 ) or placebo ( n = 22 ) for one month . Before and after treatment , blood samples were collected and the flow-mediated dilation ( FMD ) and isosorbide dinitrate ( ISDN ) -mediated dilation of the brachial artery were performed . RESULTS Baseline clinical characteristics of the allopurinol and placebo groups demonstrated no differences in terms of clinical characteristics , endothelial function and inflammatory markers . After the treatment with allopurinol , FMD was increased from 8.0 +/- 0.5 % to 11.8 +/- 0.6 % ( P < 0.01 ) , but there were no change in the placebo group . In both groups , ISDN-mediated dilation is unaffected by the treatment . As a marker of oxidative stress , allopurinol significantly reduced malondialdehyde . Moreover , myeloperoxidase levels were reduced by the treatment with allopurinol ( 56.1 +/- 3.4 ng/ml vs. 44.4 +/- 2.4 ng/ml , P < 0.05 ) but there were no change in the placebo group . Surprisingly , neither CRP nor fibrinogen levels were affected by the treatment in both groups . CONCLUSION Xanthine oxidoreductase inhibition by allopurinol in patients with metabolic syndrome reduces oxidative stress , improves endothelial function , ameliorates myeloperoxidase levels and does not have any effect on CRP and fibrinogen levels .
34895
Intervention_Pharmacological
Allopurinol
34896
Intervention_Pharmacological
allopurinol
34897
Intervention_Control
placebo
34898
Intervention_Physical
blood samples
34899
Intervention_Pharmacological
allopurinol
34900
Outcome_Physical
flow-mediated dilation ( FMD )
34901
Outcome_Physical
isosorbide dinitrate ( ISDN ) -mediated dilation
34902
Outcome_Other
clinical characteristics
34903
Outcome_Physical
, endothelial function
34904
Outcome_Physical
inflammatory markers
34905
Outcome_Physical
FMD
34906
Outcome_Physical
ISDN-mediated dilation
34907
Outcome_Physical
reduced malondialdehyde
34908
Outcome_Physical
myeloperoxidase levels
34909
Outcome_Physical
CRP nor fibrinogen levels
34910
Outcome_Physical
oxidative stress , improves endothelial function , ameliorates myeloperoxidase levels
34911
Participant_Condition
metabolic syndrome
34912
Participant_Condition
metabolic syndrome
34913
Participant_Condition
metabolic syndrome
34914
Participant_Sample-size
28
34915
Participant_Sample-size
22